Liraglutide vs Dulaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Victoza, Saxenda
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Also: Trulicity
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Key Comparison Insights
- Both Liraglutide and Dulaglutide are FDA approved medications.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Liraglutide | Dulaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Liraglutide has 97% homology to native GLP-1 with modifications for extended half-life. It slows gastric emptying, increases insulin secretion, suppresses glucagon, and acts on brain appetite centers to reduce hunger. | Dulaglutide consists of two GLP-1 analogs linked to a modified human IgG4 Fc fragment. This structure extends half-life to about 5 days, allowing weekly dosing. Works through standard GLP-1 receptor activation. |
| Common Dosing | 1.8-3 mg daily Once daily | 1.5-4.5 mg weekly Once weekly |
| Administration | Subcutaneous injection daily | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term / chronic use |
| Best Time to Take | Morning or evening, consistent daily | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | SCALE trials showed 5-10% weight loss. LEADER trial demonstrated cardiovascular benefits in diabetics. Extensive long-term safety data available. First GLP-1 approved specifically for weight management (Saxenda). | AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials. |
Frequently Asked Questions: Liraglutide vs Dulaglutide
What is the difference between Liraglutide and Dulaglutide?
Liraglutide is a weight loss peptide that an fda-approved glp-1 receptor agonist for type 2 diabetes and chronic weight management. the predecessor to semaglutide with daily dosing. Dulaglutide is a weight loss peptide that an fda-approved weekly glp-1 receptor agonist for type 2 diabetes. fused to an fc antibody fragment for extended duration of action. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Liraglutide or Dulaglutide?
Neither is universally "better" - the choice depends on your specific goals. Liraglutide is typically used for weight loss purposes, while Dulaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Liraglutide and Dulaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Liraglutide and Dulaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Liraglutide and Dulaglutide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.